Givet-5 rooms and treatment of chronic bronchitis (4 blisters x 7 tablets)

Dosage form Box of 4 blisters x 7 tablets
Specifications Montelukast

Ingredient

Composition information	Content
Montelukast	5mg

Uses

Indications

Givet - 5 drugs are indicated in the following cases:

Preventing and treating chronic bronchial asthma for adults and 6 -year -old children: Including prevention of both day and night asthma symptoms, sensitive asthma treatment for aspirin and preventing bronchospasm due to exertion.

Pharmacy

Cysteinyl Leukotrien (LTC4, LTD4, LTE4) are effective eicosanoids, secreted from many cells, including macro -moisturizer and EOSIN. These important intermediates are attached to cysteinyl leukotrien receptors (CYSLT1). CYSLT1 receptors are found in human airfields including smooth muscle cells and macrophages of airway and in other pre -inflammatory cells (including eosin leukemia and some bone marrow cells).

CYSLT is correlated with pathological physiology of asthma and allergic rhinitis. In asthma, Leukotrien intermediaries include a number of breathing effects such as bronchospasm, affecting mucus secretion, capillary permeability and an eosin cellular supplement. In allergic rhinitis, CYSLT is secreted from the nasal mucosa after exposure to allergens in the reactions in fast, slow and related phases related to allergic rhinitis symptoms. Cyslt in the nose will increase the airway resistance and congestion symptoms.

Montelukast oral form is anti -inflammatory and improves parameters of asthma inflammation. Based on biochemical and pharmacological tests, Montelukast proves high affinity and selective selection with CYSLT receptor (this effect is superior to other receptors that are also important in pharmacological, such as Prostanoid receptors, cholinergic or adrenergic).

Montelukast strongly inhibits the physiological effects of LTC4, LTDA, and LTE at CYSLT receptors without the effect of the luck. In Hen Hen, Montelukast inhibits the cysteinyl leukotrien receptors in the airway showing the ability to inhibit bronchospasm due to inhalation Ltd.

With the dose of less than 5mg that has been closed the bronchospasm caused by Ltd, Montelukast causes bronchiectasis for 2 hours after drinking, these effects are in -coate with the bronchodilator by using the subject.

pharmacokinetic

absorption

After drinking, Montelukast absorbed quickly and almost completely. With 5mg film tablets, CMAX reached 2 hours after adults drinking when hungry. Birth when drinking is 37%.

Distribution

Montelukast attaches more than 99% to plasma proteins. The distribution volume (VG) in the stable state of Montelukast is 8 - 11L.

Metabolism

Montelukast metabolizes very strongly. Cytochrom P450 3A4 and 2C9 as catalysts for Montelukast's metabolism.

Elimination

When taken, Montelukast and the metabolites of the drug are almost completely exhausted. Montelukast's plasma sale time is 2.7 - 5.5 hours in healthy young people.

Before taking Givet-5 rooms and treatment of chronic bronchitis (4 blisters x 7 tablets)

How to use

oral drugs. Take medicine with water.

Dosage

Take the drug once a day. To treat asthma, need to take medicine in the evening. With allergic rhinitis, the time to use the drug depends on the needs of each object. For patients with both asthma and allergic rhinitis, should be used once a day in the evening.

Adults, aged 15 and older with asthma or allergic rhinitis

1 tablet 10mg/day.

Children from 6 - 14 years old with asthma or allergic rhinitis

1 tablet 5mg/day.

Children from 6 months - 5 years old with asthma or allergic rhinitis

Should switch to a 4mg pack of nuggets/day.

General recommendation

Montelukast's effectiveness based on Hen's test parameters will reach 1 day. It is necessary to tell patients to continue taking the drug even when asthma attacks have been controlled, as well as in periods of severe asthma.

No dose adjustments for patients with renal impairment or patients with mild to moderate liver failure or for each gender. There is no data on drug use in patients with severe liver failure.

Alternative therapy for low -dose inhaled corticosteroids for mild persistent bronchial patients

Montelukast is not recommended to use monomers in patients with average average bronchial asthma. Only use Montelukast for replacement treatment for low -dose inhaled corticosteroids in children with mild persistent bronchial asthma if the child does not have a recent severe severe asthma attacks, but the use of oral corticosteroids and in children cannot use inhaled corticosteroids.

If the bronchial asthma is not well controlled (usually within 1 month), it may be needed or replaced with anti -inflammatory therapy. Patients should be periodically evaluated for asthma control.

Simultaneous use with other bronchial asthma treatment

When Montelukast is used for inhaled corticosteroid therapy, it is not sudden replacement of inhaled corticosteroids with Montelukast.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? In most overdose reports, no harmful reactions. The most common reactions are similar to Montelukast's safety properties including abdominal pain, drowsiness, thirst, headache, vomiting and hyperactivity. It is unclear whether Montelukast can be separated through peritoneal or dialysis.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose

Side Effects

When using Givet - 5 drugs, you may experience unwanted effects (ADR).

Very common, ADR> 1/10

Infections: upper respiratory infection.

Common, ADR> 1/100

Digestive: diarrhea, nausea, vomiting.

liver - bile: Increased serum transaminase concentration (ALT, AST).

Skin and subcutaneous tissue: rash. Other disorders: fever.

Uncommon, 1/1000

Immune: The hypersensitivity reaction includes anaphylactic shock.

Mental: Abnormal dreams include nightmares, insomnia, sleepwalking, anxiety, agitation including aggressive or hostile, depression, mental hyperactivity (including stimulation, restlessness, tremor). nerve: dizziness, drowsiness, paresthesia, reducing sensation, convulsions.

Respiratory, chest and mediastinum: nosebleeds.

digestion: dry mouth, indigestion.

Skin and subcutaneous tissue: bruising, urticaria, itching.

bone and connective tissue: joint pain, muscle pain including cramps.

Common disorders and at the position of use: weakness, fatigue, discomfort, edema.

Rare, 1/10,000

Blood and lymphatic system: Increasing bleeding trend.

Mental: Disorders of attention, memory loss.

Cardiovascular: Brush the chest drum.

Skin and subcutaneous tissue: Evaluation.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Givet medicine - 5 contraindications in case of hypersensitivity to Montelukast or any component of the drug.

Caution when using

should not use Montelukast oral forms to treat acute asthma attacks. Patients need to be instructed to use the appropriate treatment.

may have to reduce the inhaled corticosteroids gradually under the supervision of a doctor, but not to suddenly replace oral corticosteroid oral inhalation with Montelukast. Although the cause and effect has not been identified with Leukotrien receptor antagonists, it is necessary to be cautious and closely monitor clinical when reducing the dosage of corticosteroids systemic in patients using Montelukast.

When treated with Montelukast, patients with hyperchible bronchial asthma with aspirin still have to avoid using aspirin and other nonsteroidal anti -inflammatory drugs.

Warning and caution related to excipients

Preparations containing lactose, patients with rare genetic diseases galactose tolerance, lactase deficiency or glucose - galactose absorption disorders should not be used. Givet - 5 contains polysorbat 80, yellow quinolin color, yellow Sunset color can cause allergies, castor oil can cause abdominal pain, diarrhea.

The ability to drive and operate machinery

Montelukast does not affect or affect the ability to drive and operate machinery, but in very few cases, the drug can cause dizziness and drowsiness.

Pregnancy

There is not enough data to conclude that it is contacted with Montelukast. Only use drugs for pregnant women when really necessary.

Breastfeeding period

because the drug can be secreted through breast milk, only use the drug when really necessary.

Drug interaction

recommended doses in Montelukast's treatment does not significantly affect the pharmacokinetics of the following drugs: Theophylin, prednison, prednisolon, contraceptive drug (Ethinyl estradiol/norethindron 35/1), Terfenadin, Digoxin and Warfarin.

The area under the curve (AUC) of Montelukast decreased by about 40% in people with phenobarbital. Because Montelukast is metabolized by CYP 3A4, 2C8 and 2C9, it is cautious when using Montelukast together with CYP 3A4, 2C8 and 2C9 induction substances such as Phenytoin, Phenobarbital and Rifampicin, especially in children.

Montelukast does not change the metabolism of drugs that are metabolized mainly through CYP 2C8 (such as Paclitaxel, Rosiglitazon, Repaglinid).

Montelukast is the substrate of CYP 2C8 and a smaller part of 2C9, 3A4. Gemfibrozil (CYP 2C8 and 2C9 inhibitors) increase the exposure of Montelukast's system to 4.4 times. There is no need to adjust the dose of Montelukast, however, be careful about the risk of increasing unwanted effects.

Storage

In a dry place, avoid light, the temperature does not exceed 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.